356 related articles for article (PubMed ID: 28638907)
1. Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.
Bhattacharyya S; Purkait K; Mukherjee A
Dalton Trans; 2017 Jul; 46(26):8539-8554. PubMed ID: 28638907
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic Ru
Sarkar A; Acharya S; Khushvant K; Purkait K; Mukherjee A
Dalton Trans; 2019 May; 48(21):7187-7197. PubMed ID: 30601545
[TBL] [Abstract][Full Text] [Related]
3. Half-sandwich Ru(η
Huang YC; Haribabu J; Chien CM; Sabapathi G; Chou CK; Karvembu R; Venuvanalingam P; Ching WM; Tsai ML; Hsu SCN
J Inorg Biochem; 2019 May; 194():74-84. PubMed ID: 30831392
[TBL] [Abstract][Full Text] [Related]
4. Alteration of steric hindrance modulates glutathione resistance and cytotoxicity of three structurally related Ru(II)-p-cymene complexes.
Purkait K; Chatterjee S; Karmakar S; Mukherjee A
Dalton Trans; 2016 May; 45(20):8541-55. PubMed ID: 27120485
[TBL] [Abstract][Full Text] [Related]
5. [(η(6)-p-cymene)Ru(H2O)3](2+) binding capability of aminohydroxamates - A solution and solid state study.
Parajdi-Losonczi PL; Bényei AC; Kováts É; Timári I; Muchova TR; Novohradsky V; Kasparkova J; Buglyó P
J Inorg Biochem; 2016 Jul; 160():236-45. PubMed ID: 26971623
[TBL] [Abstract][Full Text] [Related]
6. Ruthenium(ii) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines.
Mandal P; Kundu BK; Vyas K; Sabu V; Helen A; Dhankhar SS; Nagaraja CM; Bhattacherjee D; Bhabak KP; Mukhopadhyay S
Dalton Trans; 2018 Jan; 47(2):517-527. PubMed ID: 29235601
[TBL] [Abstract][Full Text] [Related]
7. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.
Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F
Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875
[TBL] [Abstract][Full Text] [Related]
8. Organometallic Ru(II), Rh(III) and Re(I) complexes of sterane-based bidentate ligands: synthesis, solution speciation, interaction with biomolecules and anticancer activity.
Pivarcsik T; Kiss MA; Rapuš U; Kljun J; Spengler G; Frank É; Turel I; Enyedy ÉA
Dalton Trans; 2024 Mar; 53(11):4984-5000. PubMed ID: 38406993
[TBL] [Abstract][Full Text] [Related]
9. Comparative solution equilibrium studies of antitumor ruthenium(η
Dömötör O; Pape VFS; May NV; Szakács G; Enyedy ÉA
Dalton Trans; 2017 Mar; 46(13):4382-4396. PubMed ID: 28287667
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic Ruthenium(II) Complexes of Pyrazolylbenzimidazole Ligands That Inhibit VEGFR2 Phosphorylation.
Chakraborty A; Roy S; Chakraborty MP; Roy SS; Purkait K; Koley TS; Das R; Acharya M; Mukherjee A
Inorg Chem; 2021 Dec; 60(23):18379-18394. PubMed ID: 34780170
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
[TBL] [Abstract][Full Text] [Related]
12. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
[TBL] [Abstract][Full Text] [Related]
13. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
14. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
15. Disruption of the Microtubule Network and Inhibition of VEGFR2 Phosphorylation by Cytotoxic
Acharya S; Maji M; Chakraborty MP; Bhattacharya I; Das R; Gupta A; Mukherjee A
Inorg Chem; 2021 Mar; 60(5):3418-3430. PubMed ID: 33554592
[TBL] [Abstract][Full Text] [Related]
16. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
17. Solution equilibrium, structural and cytotoxicity studies on Ru(η
Dömötör O; Kiss MA; Gál GT; May NV; Spengler G; Nové M; Gašparović AČ; Frank É; Enyedy ÉA
J Inorg Biochem; 2020 Jan; 202():110883. PubMed ID: 31689626
[TBL] [Abstract][Full Text] [Related]
18. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
19. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
[TBL] [Abstract][Full Text] [Related]
20. Solution equilibria of anticancer ruthenium(II)-(η(6)-p-cymene)-hydroxy(thio)pyr(id)one complexes: impact of sulfur vs. oxygen donor systems on the speciation and bioactivity.
Enyedy EA; Sija E; Jakusch T; Hartinger CG; Kandioller W; Keppler BK; Kiss T
J Inorg Biochem; 2013 Oct; 127():161-8. PubMed ID: 23721887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
